PPCB Overview

Propanc Biopharma, Inc. is an Australia-based biopharmaceutical company. The Company is focused on the development of novel cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. The Company has developed a rational, composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its lead product candidate, PRP, is a variation upon its formulation and involves pro-enzymes, the inactive precursors of enzymes. PRP is a long-term therapy based on pancreatic proenzyme formulation to prevent tumor recurrence and metastasis. PRP is a patented, formulation consisting of two proenzymes mixed in a synergetic ratio. PRP is in the preclinical phase of development. Its drug pipeline also includes POP1.

Wall Street analysts forecast PPCB stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PPCB is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Propanc Biopharma Inc revenue for the last quarter amounts to 0.00 USD, decreased

Propanc Biopharma Inc. EPS for the last quarter amounts to -7.09 USD, decreased -97.73

Propanc Biopharma Inc (PPCB) has 1 emplpoyees as of June 16 2026.

Today PPCB has the market capitalization of 4.90M USD.